Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma - Takeaways - MDSpire

Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma

  • By

  • Guofu Lin

  • Lanlan Lin

  • Jianming Zhao

  • Gongping Chen

  • May 25, 2026

  • 0 min

Share

  • 1

    ADAM9 is identified as a crucial mediator of efferocytosis in lung adenocarcinoma, influencing tumor progression and immune evasion.

  • 2

    A prognostic model based on eleven efferocytosis-related genes, including ADAM9, stratifies LUAD patients into high- and low-risk groups.

  • 3

    High ADAM9 expression correlates with immunosuppressive microenvironments characterized by increased M2 macrophages and neutrophils.

  • 4

    Single-cell analysis reveals ADAM9 enrichment in M2 macrophage subsets, linking its expression to macrophage differentiation.

  • 5

    In vitro studies show that ADAM9 silencing regulates M2 macrophage efferocytosis and polarization, impacting tumor cell proliferation via IL-6/STAT3.

Original Source(s)

Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma

  • by Guofu Lin, Lanlan Lin, Jianming Zhao, Gongping Chen

  • May 25, 2026

Related Content

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report